Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
Cellectar Biosciences (NASDAQ: CLRB) has entered into a multi-year supply agreement with Nusano for the provision of iodine-125 (I-125) and actinium-225 (Ac-225) isotopes. The partnership will support Cellectar's radiotherapeutic pipeline development, including CLR 125 for triple negative breast cancer and CLR 225 for pancreatic cancer.
The isotopes will be produced at Nusano's next-generation facility in Utah, ensuring uninterrupted access to these essential materials for both clinical development and future commercial needs. This strategic partnership addresses critical supply chain challenges in the production of rare medical radioisotopes at commercial scale.
Cellectar Biosciences (NASDAQ: CLRB) ha stipulato un accordo pluriennale di fornitura con Nusano per la fornitura di isotopi di iodio-125 (I-125) e attinio-225 (Ac-225). Questa collaborazione sosterrà lo sviluppo della pipeline radioterapeutica di Cellectar, inclusi CLR 125 per il carcinoma mammario triplo negativo e CLR 225 per il tumore al pancreas.
Gli isotopi saranno prodotti presso la struttura all'avanguardia di Nusano nello Utah, garantendo un accesso continuo a questi materiali essenziali sia per lo sviluppo clinico che per le future esigenze commerciali. Questa partnership strategica affronta le sfide critiche della catena di approvvigionamento nella produzione su scala commerciale di radioisotopi medici rari.
Cellectar Biosciences (NASDAQ: CLRB) ha firmado un acuerdo de suministro plurianual con Nusano para la provisión de isotopos de yodo-125 (I-125) y actinio-225 (Ac-225). La colaboración apoyará el desarrollo de la cartera radioterapéutica de Cellectar, incluyendo CLR 125 para cáncer de mama triple negativo y CLR 225 para cáncer de páncreas.
Los isotopos serán producidos en la instalación de última generación de Nusano en Utah, asegurando un acceso ininterrumpido a estos materiales esenciales tanto para el desarrollo clínico como para futuras necesidades comerciales. Esta asociación estratégica aborda los desafíos críticos en la cadena de suministro para la producción a escala comercial de radioisótopos médicos raros.
Cellectar Biosciences (NASDAQ: CLRB)는 Nusano와 요오드-125(I-125) 및 악티늄-225(Ac-225) 동위원소 공급을 위한 다년간 공급 계약을 체결했습니다. 이 파트너십은 삼중음성 유방암 치료제 CLR 125와 췌장암 치료제 CLR 225를 포함한 Cellectar의 방사선 치료제 파이프라인 개발을 지원할 것입니다.
동위원소는 Utah에 위치한 Nusano의 차세대 시설에서 생산되어 임상 개발과 향후 상업적 수요 모두에 필수적인 자재에 대한 지속적인 접근을 보장합니다. 이 전략적 파트너십은 희귀 의료 방사성 동위원소의 상업적 대규모 생산에서 발생하는 공급망 문제를 해결합니다.
Cellectar Biosciences (NASDAQ : CLRB) a conclu un accord de fourniture pluriannuel avec Nusano pour la fourniture d'isotopes iode-125 (I-125) et actinium-225 (Ac-225). Ce partenariat soutiendra le développement du pipeline radiothérapeutique de Cellectar, incluant CLR 125 pour le cancer du sein triple négatif et CLR 225 pour le cancer du pancréas.
Les isotopes seront produits dans l'installation de nouvelle génération de Nusano dans l'Utah, garantissant un accès ininterrompu à ces matériaux essentiels pour le développement clinique ainsi que pour les besoins commerciaux futurs. Ce partenariat stratégique répond aux défis critiques de la chaîne d'approvisionnement dans la production à l'échelle commerciale d'isotopes médicaux rares.
Cellectar Biosciences (NASDAQ: CLRB) hat eine mehrjährige Liefervereinbarung mit Nusano über die Bereitstellung von Iod-125 (I-125) und Actinium-225 (Ac-225) Isotopen abgeschlossen. Die Partnerschaft unterstützt die Entwicklung von Cellectars radiotherapeutischer Pipeline, einschließlich CLR 125 für triple-negativen Brustkrebs und CLR 225 für Bauchspeicheldrüsenkrebs.
Die Isotope werden in Nusanos hochmoderner Anlage in Utah produziert, was einen ununterbrochenen Zugang zu diesen wichtigen Materialien sowohl für die klinische Entwicklung als auch für zukünftige kommerzielle Bedürfnisse sicherstellt. Diese strategische Partnerschaft adressiert kritische Herausforderungen in der Lieferkette bei der kommerziellen Produktion seltener medizinischer Radioisotope.
- Secured long-term supply of essential isotopes I-125 and Ac-225 for clinical trials and commercial needs
- Partnership enables uninterrupted access to rare and hard-to-produce medical radioisotopes
- Agreement supports advancement of multiple clinical programs including treatments for triple negative breast cancer and pancreatic cancer
- None.
Insights
Cellectar secures critical isotope supply for cancer therapies, removing development bottleneck and enabling clinical advancement.
This supply agreement with Nusano represents a significant strategic development for Cellectar's radiotherapeutic pipeline. Securing reliable access to both iodine-125 and actinium-225 addresses one of the fundamental challenges in radiopharmaceutical development - consistent isotope supply. This is particularly noteworthy for actinium-225, which has been notoriously difficult to source in quantities sufficient for clinical development and commercialization.
The agreement specifically supports Cellectar's CLR-125 program targeting triple-negative breast cancer (a particularly aggressive cancer with limited treatment options) and CLR-225 for pancreatic cancer (one of the deadliest cancer types with dismal survival rates). Both programs utilize Cellectar's phospholipid drug conjugate (PDC) delivery platform, which preferentially targets cancer cells.
Nusano's next-generation facility in Utah represents a technological advance in isotope production, potentially overcoming supply limitations that have historically constrained radiopharmaceutical development. For Cellectar, this eliminates a critical supply chain vulnerability that could have otherwise delayed clinical trials or limited commercial scaling.
This partnership effectively transforms isotope access from a potential bottleneck into a strategic advantage, enabling Cellectar to proceed with clinical development without the supply uncertainties that often plague this sector. With radiopharmaceuticals gaining significant traction in oncology, securing reliable isotope supply positions Cellectar competitively in this rapidly evolving therapeutic space.
Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225
Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative Breast Cancer
FLORHAM PARK, N.J. and WEST VALLEY CITY, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Nusano, a physics company transforming the production of radioisotopes, today announced the signing of a multi-year supply agreement in which Nusano will provide Cellectar with iodine-125 (I-125) and actinium-225 (Ac-225) for its clinical studies and future commercial needs.
“Securing a reliable supply of both iodine-125 and actinium-225 is a critical milestone in advancing our targeted radiotherapy programs,” said James Caruso, chief executive officer of Cellectar. “This agreement ensures uninterrupted access to these essential isotopes, providing the necessary clinical development supply for our innovative clinical stage programs, including CLR 125 for triple negative breast cancer and CLR 225 for pancreatic cancer. We look forward to partnering with Nusano to support our mutual vision to deliver new radiotherapeutics to patients in critical need of novel treatment options. I-125 and Ac-225 will be produced at Nusano’s next-generation radioisotope production facility in Utah. This production platform enables the creation of rare and hard-to-produce medical radioisotopes in quantities needed for commercial-stage therapeutics and diagnostics.”
“The power and flexibility of the Nusano production platform is designed to solve the critical supply chain challenges and enable innovation across multiple industries,” said Chris Lowe, chief executive officer of Nusano. “We’re proud to support Cellectar with critical isotope supplies so they can advance their product pipeline and create new, personalized cancer treatments.”
About Nusano
Nusano is a privately held physics company committed to: bringing supply stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market, serving industrial and commercial markets dependent on reliable access to high quality radioisotopes for their products and services, and enabling next-generation energy solutions. Nusano’s breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. For more, please visit nusano.com.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope), for which the FDA has granted Breakthrough Therapy Designation; CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Forward Looking Statement Disclaimer
This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to identify suitable collaborators, partners, licensees or purchasers for our product candidates and, if we are able to do so, to enter into binding agreements with regard to any of the foregoing, or to raise additional capital to support our operations, or our ability to fund our operations if we are unsuccessful with any of the foregoing. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2024, and our Form 10-Q for the quarter ended March 31, 2025. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.
Cellectar Biosciences Contact:
Investors:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com
Nusano Contacts:
Media:
Scott Larrivee
608-345-6629
larrivee@nusano.com
Investors:
Joyce Allaire
LifeSci Advisors, LLC
212-915 2569
jallaire@lifesciadvisors.com
FAQ
What is the purpose of Cellectar Biosciences (CLRB) partnership with Nusano?
Which cancer treatments will benefit from CLRB's isotope supply agreement?
Where will Nusano produce the isotopes for Cellectar Biosciences?
How does the Nusano agreement impact CLRB's clinical development?
